Hoag Family Cancer Institute Overview

Over 4,000 individuals seek cancer care at Hoag every year, making it the largest volume provider of cancer care in Orange County, and the largest program in Southern California outside of Los Angeles. Since its inception, Hoag Family Cancer Institute’s commitment to providing the highest quality cancer care to the communities Hoag serves has been evidenced by exceptional patient outcomes and various recognition awards.

Hoag was designated High Performing in Cancer in U.S. News & World Report’s 2018-2019 Best Hospitals Rankings.

Multidisciplinary subspecialized collaboration across the continuum of cancer care is the focus for continued programmatic development at Hoag Family Cancer Institute. The Institute’s site-specific cancer programs offer patients access to high risk services, prevention and early detection screenings or programs, advanced diagnostic and treatment capabilities, including access to new treatments through clinical trials including Phase I care, subspecialized physicians in oncologic surgery, medical oncology, radiation oncology, radiology and pathology, integration of precision medicine, and a robust supportive infrastructure that helps patients optimize quality of life from diagnosis through survivorship. 12 site-specific tumor boards that each meet several times per month connect specialists who discuss cases and ensure a team-based, coordinated approach. Six nurse navigators, who focus on patients with one or two types of cancer guide and assist patients through their treatment and the health care system.

In 2013, Hoag Family Cancer Institute and USC Norris Comprehensive Cancer Center established an alliance, integrating the unique aspects of academic medicine and community-based cancer care. The last five years have seen significantly expanded clinical research through Hoag Family Cancer Institute’s participation in national registries and opening of phase I, II, and first in man clinical trials as part of the Hoag/USC alliance.

Advanced technology and specialized facilities at the Patty & George Hoag Cancer Center in Newport Beach and Hoag Cancer Center Irvine are fundamental to the Institute. But perhaps the Institute’s greatest asset is its people. Renowned subspecialty physicians, Oncology Certified Nurses (OCN®), therapists, dietitians, nurse navigators, social workers, and Hoag Family Cancer Institute staff are all guided by a patient-first mentality. Hoag boasts 13 endowed chairs, unique for a non-academic hospital. Four of these endowed chairs are held by Hoag Family Cancer Institute medical directors.

The following programs and services, each reflected in this Annual Report, are the platform for Hoag Family Cancer Institute’s delivery of integrated, comprehensive cancer care:

  • Bone & Soft Tissue Sarcoma Program
  • Brain, Skull Base & Pituitary Tumors Programs (shared with Pickup Family Neurosciences Institute)
  • Breast Cancer Program (shared with Hoag Women’s Health Institute)
  • Colorectal Cancer Program
  • Endocrine Cancer Program
  • Esophageal & Gastric Cancer Program
  • Gynecologic Cancer Program (shared with Hoag Women’s Health Institute)
  • Head & Neck Cancer Program
  • Lung Cancer Program
  • Melanoma/Advanced Skin Cancer Program
  • Pancreas & Hepatobiliary Cancer Program
  • Precision Medicine Program
  • Urologic Cancer Program
  • Clinical Research Program
  • Hereditary Cancer Program
  • Integrated Cancer Support Services
  • Medical Oncology & Infusion Services
  • Pathology
  • Radiation Oncology
  • Radiology

DATA DEFINITIONS

This report includes data reflecting program volumes (analytic and non-analytic) and Surveillance Epidemiologic End Results (SEER). Key terms are defined below:

Analytic Cases: Patients who were diagnosed at the institution and/or received cancer therapy at the institution within four months of diagnosis.

Non-Analytic Cases: Cases where institution participated in the diagnostic workup, but the treatment was provided elsewhere; patient received diagnosis and all of the first course of treatment elsewhere and the patient presented at the reporting institution with recurrence, disease history only; limited information on the original diagnosis and/or first course of treatment exist.

Surveillance Epidemiologic End Results (SEER) Program of the National Cancer Institute: Registry data is relayed
to state and national cancer databases. [National Cancer Act 1971, Cancer Registries Amendment Act 1992].

Cancer Registries: Hospital-based; established to collect cancer-related information including social demographics, histology, stage, treatment, date of diagnosis, and date of death.

Relative Survival (RS) SEER: Estimate of death from cancer

  • Adjusts for competing causes of death by age and gender
  • Approximates cancer as cause of death

Data Usage

  • SEER annually publishes national cancer data
  • SEER data is the most reliable national data currently available
  • External (extramural) benchmark comparisons: Compare institution’s own 5-year relative survival data to figures published annually by SEER
  • Internal (intramural) comparisons: Institution’s own cancer registry data can be used to establish recent survival rates and historical survival rates as benchmarks

Number of Cancer Surgeries (Volume) Performed in California Hospitals Report (Office of Statewide Health Planning and Development [OSHPD]): The data set contains the number (volume) for 11 types of cancer (bladder, breast, brain, colon, esophagus, liver, lung, pancreas, prostate, rectum, and stomach) surgeries performed in California hospitals in 2017. For all types of cancer surgeries, except breast cancer, the dataset contains surgeries performed in the inpatient hospital setting. For breast cancer surgeries, this dataset includes procedures performed in inpatient and outpatient settings.

For more information call: 949-722-6237